
20. The composition of claim 19 wherein said immunogen is herpes simplex antigen HSV2gD.

C2 21. An injectable pharmaceutical composition comprising the composition of claim 20.

22. A method of immunizing an individual against a herpes simplex virus infection comprising administering to said individual a plasmid of claim 20.

33. A method of inducing an immune response in an individual against an immunogen comprising administering to said individual:

a nucleic acid molecule comprising a nucleotide sequence that encodes said immunogen operable linked to regulatory elements; and

C3 a nucleic acid molecule comprising a nucleotide sequence that encodes said immunomodulating protein operably linked to regulatory elements, wherein said immunomodulating protein is selected from the group consisting of : MCP-1, MIP-1a, MIP-1 β , IL-8, RANTES, L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1, Mac-1, p150.95, PECAM, ICAM-1, ICAM-2, ICAM-3, CD2, LFA-3, M-CSF, G-CSF, IL-4, mutant forms of IL-18, CD40, CD40L, vascular growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Flt, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4, DR5, KILLER, TRAIL-R2, TRICK2, DR6, and Caspase ICE.
